Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Parasite Alleles Linked to Severe Illness in Newborns

By LabMedica International staff writers
Posted on 26 Apr 2012
Strains of the Toxoplasma gondii parasite have been identified that are most strongly associated with premature births and severe birth defects.

A new blood test has been developed detect the presence of strain-specific antibodies to pinpoint T. More...
gondii strains that children acquire from their acutely infected mothers while in the womb.

Scientists at the US National Institute of Allergy and Infectious Diseases (NIAID; Bethesda, MD, USA) applied the test to blood samples collected between 1981 and 2009 as part of the National Collaborative Chicago-Based Congenital Toxoplasmosis Study. Sera were obtained from 183 mothers who transmitted T. gondii to their fetuses and 151 infants, most diagnosed with substantial disease as newborns.

Studies performed included the Sabin-Feldman Dye test; immunoglobulin G (IgG) and immunoglobulin M (IgM) enzyme linked immunosorbent assays (ELISA) on maternal serum; IgM immunosorbent agglutination assay on newborn samples; immunoglobulin A (IgA) ELISA on mother and child sera; differential agglutination tests and avidity assays on maternal samples. Presence of strain-specific antibodies in people infected by parasites with type II or non-II alleles was determined in an ELISA using polymorphic peptides derived from two T. gondii dense granule proteins (GRA6 and GRA7) and two control peptides coupled to keyhole limpet hemocyanin (Biosource; Camarillo, CA, USA).

The scientists found evidence of either type II or not exclusively type II strains (NE-II) infections in 183 of the mother-child pairs in the national congenital toxoplasmosis study. The NE-II parasites were more likely to be associated with premature birth, and infants infected with these strains were more likely to have severe manifestations of disease than infants infected by type II parasites. Severe eye damage was seen in 59 out of 88 (67%) of NE-II cases, while such eye damage was present in only 18 out of 46 (39%) of type II cases.

Rima McLeod, MD, from the University of Chicago (IL, USA) and principal author of the study, said, "In the United States, obstetrical screening for Toxoplasma infection is rarely practiced. This new study underscores the value of identifying all patients who will benefit from treatment and suggests that widespread screening and treatment of pregnant women who are infected could prevent infants from suffering eye and brain damage due to congenital toxoplasmosis." The study was published on April 11, 2012, in the journal Clinical Infectious Diseases.

Related Links:

US National Institute of Allergy and Infectious Diseases
Biosource
University of Chicago



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.